M
M. Cavallin
Researcher at University of Padua
Publications - 30
Citations - 1608
M. Cavallin is an academic researcher from University of Padua. The author has contributed to research in topics: Hepatorenal syndrome & Terlipressin. The author has an hindex of 12, co-authored 30 publications receiving 1216 citations.
Papers
More filters
Journal ArticleDOI
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Paolo Caraceni,Oliviero Riggio,Paolo Angeli,Carlo Alessandria,Sergio Neri,Francesco Giuseppe Foschi,F. Levantesi,Aldo Airoldi,S. Boccia,Gianluca Svegliati-Baroni,Stefano Fagiuoli,Roberto Giulio Romanelli,Raffaele Cozzolongo,Vito Di Marco,Vincenzo Sangiovanni,Filomena Morisco,Pierluigi Toniutto,Annalisa Tortora,Rosanna De Marco,Mario Angelico,Irene Cacciola,Gianfranco Elia,Alessandro Federico,Sara Massironi,Riccardo Guarisco,Alessandra Galioto,Giorgio Ballardini,Maria Rendina,Silvia Nardelli,Salvatore Piano,Chiara Elia,Loredana Prestianni,Federica Mirici Cappa,Lucia Cesarini,L. Simone,Chiara Pasquale,M. Cavallin,Alida Andrealli,F. Fidone,Matteo Ruggeri,A. Roncadori,Maurizio Baldassarre,Manuel Tufoni,Giacomo Zaccherini,Mauro Bernardi,Marco Domenicali,Ferdinando Giannone,Manuela Merli,Stefania Gioia,Silvano Fasolato,Antonietta Sticca,Daniela Campion,A. Risso,Giorgio Maria Saracco,D. Maiorca,Agostino Rizzotto,Arianna Lanzi,Elga Neri,Anna Visani,Antonio Mastroianni,A Alberti,Chiara Mazzarelli,Marcello Vangeli,Marco Marzioni,Francesca Capretti,Alba Kostandini,G. Magini,M. Colpani,Giacomo Laffi,T Gabbani,Maria Marsico,M. Zappimbulso,Josè Petruzzi,Vincenza Calvaruso,Giovanni Parrella,Nicola Caporaso,Francesco Auriemma,Maria Guarino,Fabio Pugliese,Antonio Gasbarrini,Pietro Leo,Francesco De Leonardis,A. Pecchioli,Piera Rossi,Giovanni Raimondo,Elisa Negri,Marcello Dallio,Carmelina Loguercio,Dario Conte,Natascia Celli,R. Bringiotti,N.M. Castellaneta,Francesco Salerno +92 more
TL;DR: Long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis in this trial.
Journal ArticleDOI
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
M. Cavallin,Patrick S. Kamath,Manuela Merli,Silvano Fasolato,Pierluigi Toniutto,Francesco Salerno,Mauro Bernardi,Roberto Giulio Romanelli,C. Colletta,F. Salinas,Antonio Di Giacomo,Lorenzo Ridola,Ezio Fornasiere,Paolo Caraceni,Filippo Morando,Salvatore Piano,Angelo Gatta,Paolo Angeli +17 more
TL;DR: Tepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment and midodrine and octreotide plus albumin are used as an alternative treatment of HRS.
Journal ArticleDOI
Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites
Salvatore Piano,S. Rosi,Giulio Maresio,Silvano Fasolato,M. Cavallin,Antonietta Romano,Filippo Morando,Elisabetta Gola,Anna Chiara Frigo,Angelo Gatta,Paolo Angeli +10 more
TL;DR: Conventional criterion is more accurate than AKIN criteria in the prediction of in-hospital mortality in patients with cirrhosis and ascites and the addition of either the progression of AKIN stage or the cut-off of sCr ≥ 1.5mg/dl to theAKIN criteria improves their prognostic accuracy.
Journal ArticleDOI
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
M. Cavallin,Salvatore Piano,Antonietta Romano,Silvano Fasolato,Anna Chiara Frigo,Gianpiero Benetti,Elisabetta Gola,Filippo Morando,M. Stanco,S. Rosi,Antonietta Sticca,Umberto Cillo,Paolo Angeli +12 more
TL;DR: Terlipressin given by continuous intravenous infusion is better tolerated than intravenous boluses in the treatment of type 1 HRS, and it is effective at doses lower than those required for intravenousbolus administration.
Journal ArticleDOI
The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
Salvatore Piano,Silvano Fasolato,F. Salinas,Antonietta Romano,Marta Tonon,Filippo Morando,M. Cavallin,Elisabetta Gola,Antonietta Sticca,Arianna Loregian,Giorgio Palù,Giacomo Zanus,Marco Senzolo,Patrizia Burra,Umberto Cillo,Paolo Angeli +15 more
TL;DR: The combination of meropenem plus daptomycin is more effective than ceftazidime as empirical antibiotic treatment of nosocomial SBP and is a strong predictor of 90‐day survival in patients with nosocomials SBP.